RITTENHOUSE v. GLAXOSMITHKLINE

CourtDistrict Court, E.D. Pennsylvania
DecidedDecember 30, 2021
Docket2:21-cv-01836
StatusUnknown

This text of RITTENHOUSE v. GLAXOSMITHKLINE (RITTENHOUSE v. GLAXOSMITHKLINE) is published on Counsel Stack Legal Research, covering District Court, E.D. Pennsylvania primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
RITTENHOUSE v. GLAXOSMITHKLINE, (E.D. Pa. 2021).

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF PENNSYLVANIA

JENNIFER RITTENHOUSE, CIVIL ACTION Plaintiff,

v.

GLAXOSMITHKLINE, NO. 21-1836 Defendant.

MEMORANDUM OPINION

Defendant GlaxoSmithKline, LLC (“GSK”) moves to compel arbitration of Plaintiff Jennifer Rittenhouse’s employment discrimination claims and stay proceedings pursuant to the Federal Arbitration Act (“FAA”), 9 U.S.C. §§ 1-14.1 For the following reasons, its motion shall be granted. The arbitration agreement at issue in this case is part of GSK’s dispute resolution program entitled “Help Employees Achieve Resolution of Their Concerns at Work” (“HEAR Program”). The program aims to handle workplace complaints in four-steps. At each step, the methods used to resolve complaints are progressively escalated, with the fourth step of the program culminating in arbitration. GSK first unveiled the program to its employees, including Rittenhouse, on August 1, 2018 through an email titled “Important – Your action required: new HEAR program for resolving concerns at work.” This email explained the four steps of the

1 This is GSK’s second motion to compel arbitration. The Court denied its first one without prejudice because the Complaint did not mention the parties’ agreement to arbitrate claims, but granted limited discovery, per Guidotti v. Legal Helpers Debt Resolution, L.L.C., 716 F.3d 764, 775-76 (3d Cir. 2013), on the validity of the agreement to arbitrate. Now the discovery has been taken, GSK’s second motion is evaluated under the standards governing summary judgment, id. at 776, i.e., the motion will be granted if GSK “shows there is no genuine dispute as to any material fact and the movant is entitled to judgment as a matter of law.” Fed R. Civ. P. 56(a). The facts, and all reasonable inferences drawn therefrom, must be viewed in the light most favorable to the party opposing summary judgment. Scott v. Harris, 550 U.S. 372, 378 (2007). The burden of proof, however, shifts with respect to Rittenhouse’s defenses against the agreement’s validity and enforceability. See Green Tree Fin. Corp.-Alabama v. Randolph, 531 U.S. 79, 91-92 (2000); Bracy v. Macy’s Retail Holdings, Inc., 2020 WL 1953647, at *6 (E.D. Pa. Apr. 23, 2020) (“Plaintiff, as the party seeking to avoid arbitration, bears the burden of proving invalidity of the arbitration agreement.”). HEAR Program, explained what arbitration entails, and advised employees that they had one month to decide whether to participate in the arbitration portions of the HEAR Program. The email detailed the steps an employee needed to take to opt out: first, the employee was directed to a link to the HEAR website to “understand more about mediation and arbitration, review the

HEAR Legal Agreement, which contains the terms, features and details of the program, and read the FAQs”; if the employee chose to opt out, then she was directed to “complete, sign and submit the HEAR Opt-Out Form – available on the HEAR site – by midnight on August 31, 2018.” The employee was further warned that, “[i]f you continue your employment with GSK/ViiV after midnight on August 31 without opting out, you will have accepted the terms and conditions of the HEAR Legal Agreement and will be covered by all 4 steps of the HEAR program, including mediation and arbitration.” The HEAR website included more descriptions of the HEAR Program, a frequently asked questions page, and the arbitration agreement. The arbitration agreement could be accessed via hyperlinks highlighted in blue text throughout the front page of the site. It could also be

accessed by clicking “HEAR Legal Agreement” on the menu bar located on the left-side of the webpage. In relevant part, the agreement provided, “Except as included in section 2 below, ‘Claims Not Covered by this Agreement,’ all concerns, disputes, claims, complaints, or controversies that involve legally protected rights (‘Claims’) that you have now or may have in the future against GSK/ViiV . . . arising out of and/or directly or indirectly related to your application for employment with GSK/ViiV, and/or your employment with GSK/ViiV . . . and/or the termination of your employment with GSK/ViiV. . . .” and expressly included claims arising under Title VII and the ADEA. Before the August 31, 2018 opt-out deadline passed, Rittenhouse received an email from her supervisor, Magdalene Pedersen. She forwarded GSK’s first email with a note to, “prompt your teams to ensure they’re making a decision about opting in/opting out of the HEAR programme by 31 August.” The email further noted that although supervisors, such as Pedersen and Rittenhouse, “cannot provide advice or guidance on the decision” they should make sure

employees were aware of the deadline. At some point prior to the deadline, Rittenhouse states in an affidavit that she asked Pedersen questions regarding the HEAR program and was told “You don’t need to do anything.” Based on this, Rittenhouse understood that by not taking further action, she would not participate in the program. Contemporaneous with Pedersen’s email, also before the opt-out deadline, GSK sent a second email which advised employees no less than three times that they could opt out of the arbitration portion of the HEAR program and that they had until August 31 to do so. This email, in three places, also contained a hyperlink to the HEAR website again encouraging employees to review the HEAR Legal Agreement. It made clear that, “[i]t is only if you choose to opt out that you need to take action. You must complete, sign, and submit the HEAR Opt-Out Form,

available on the HEAR site, by midnight on August 31, 2018. You will receive email confirmation of your decision to opt out, and a confidential record of your choice will be maintained by HR.” Prior to the deadline, Rittenhouse also received two GSK publications, an email newsletter and an article on the company’s internal “intranet.” The intranet article encouraged employees to review the agreement and also advised them of the steps they needed to take to opt out of the arbitration component. It further reminded them that they would be deemed to have agreed to arbitrate covered complaints if they did not expressly opt-out of the program before the deadline. The newsletter contained a link which asked, “Have you seen your HEAR email? Have you decided which choice is best for you?” If an employee clicked the link, she would be directed to the intranet article. The deadline came and went, and Rittenhouse did not opt out of the arbitration component of the HEAR Program. At no point did GSK separately mail or email the HEAR

Legal Agreement to its employees; it was only available for them to review on the HEAR website. Though Rittenhouse received and opened all the emails, and even forwarded one to other employees, Rittenhouse’s opposition to GSK’s motion to compel arbitration is based on a sworn affidavit in which she avers that she never read the HEAR Legal Agreement and did not agree or intend to agree to it.2 For the reasons that follow, this argument is unavailing. Beginning with basic principles, the FAA “establishes a strong federal policy in favor of compelling arbitration over litigation[,]” Sandvik AB v. Advent Int’l Corp., 220 F.3d 99, 104 (3d Cir. 2000), so long as the parties agreed to arbitrate their disputes. See Granite Rock Co. v. Int’l Broth. of Teamsters, 561 U.S.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

First Options of Chicago, Inc. v. Kaplan
514 U.S. 938 (Supreme Court, 1995)
Green Tree Financial Corp.-Alabama v. Randolph
531 U.S. 79 (Supreme Court, 2000)
Scott v. Harris
550 U.S. 372 (Supreme Court, 2007)
Guidotti v. Legal Helpers Debt Resolution, L.L.C.
716 F.3d 764 (Third Circuit, 2013)
Kirleis v. Dickie, McCamey & Chilcote, P.C.
560 F.3d 156 (Third Circuit, 2009)
United States v. Starnes
583 F.3d 196 (Third Circuit, 2009)
Morales v. Sun Constructors, Inc.
541 F.3d 218 (Third Circuit, 2008)
Quiles v. Financial Exchange Co.
879 A.2d 281 (Superior Court of Pennsylvania, 2005)
Aliments Krispy Kernels, Inc. v. Nichols Farms
851 F.3d 283 (Third Circuit, 2017)

Cite This Page — Counsel Stack

Bluebook (online)
RITTENHOUSE v. GLAXOSMITHKLINE, Counsel Stack Legal Research, https://law.counselstack.com/opinion/rittenhouse-v-glaxosmithkline-paed-2021.